MedTrace Logo

Data on Oral Contraceptives Compliance in Non Stop Regimen

NCT01185678 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8416

Last updated 2013-06-27

No results posted yet for this study

Summary

Adherence to the dosing scheme is the principal element of COC efficiency. On the other hand noncompliance seemed to be an inseparable element of any oral treatment. The aim of the study is to evaluate in everyday practice the relation between dosage errors and indicated factors, potentially influencing the compliance with the dosing scheme.

Conditions

  • Contraception

Interventions

DRUG

Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)

One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Poland

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185678 on ClinicalTrials.gov